The New Drexler Ryan Charles Holding in Musclepharm Corp
Drexler Ryan Charles filed with the SEC SC 13D/A form for Musclepharm Corp. The form can be accessed here: 000114420416134521. As reported in Drexler Ryan Charles’s form, the filler as of late owns 45.2% or 10,156,020 shares of the Consumer Staples–company.
Musclepharm Corp stake is a new one for the and it was filed because of activity on November 10, 2016. We feel this shows Drexler Ryan Charles’s positive view for the stock.
Reasons Why Drexler Ryan Charles Bought – Musclepharm Corp Stock
Purpose of Transaction
The Reporting Person is engaged in the investmentbusiness and has extensive experience in the vitamin and supplement industry. In pursuing investment opportunities, the ReportingPerson reviews the operations, capital structure and markets of companies, such as the Issuer. Based on his review and knowledgeof the industry, the Reporting Person made the decision to causeConsac to purchase the shares of Common Stock previouslyreported as beneficially owned by the Reporting Person in open market transactions for investment purposes. The ReportingPerson was appointed to the Board of Directors of the Issuer and elected Chairman of the Board in June 2015, and in connectiontherewith received shares of restricted stock of the Issuer. In December 2015, the Reporting Person entered into the First ConvertibleNote (as defined below) to assist the Issuer with working capital needs. The Reporting Person subsequently was appointed InterimPresident, Interim CEO and Executive Chairman of the Board of Directors of the Issuer and, in connection with such service, acquired options of the Issuer as equity awards. The Reporting Person acquired the Second ConvertibleNote and shares of Common Stock reported as beneficially owned to assist the Issuer in paying amounts owed by the Issuer pursuantto a Settlement Agreement entered into on November 7, 2016 in connection with a dispute arising out of a manufacturing agreement.The Reporting Person holds all shares reported as beneficially owned for investment purposes.
The Reporting Person is Interim President, InterimCEO and Executive Chairman of the Board of Directors of the Issuer. In these capacities the Reporting Person takes, and willcontinue to take, an active role in the Issuer’s management and strategic direction. In addition, in connection withhis employment with the Issuer, the Reporting Person may be entitled to cash and other non-equity compensation in connection witha sale of the Issuer or other transaction of the nature described below.
|CUSIP No. 627335201||13D/A|
Other than as described above, the Reporting Persondoes not have any current plans or proposals, but may in the future propose one or more actions, which would result in any of thefollowing:
|(a)||the acquisition by any person of additional securitiesof the Issuer, or the disposition of securities of the Issuer;|
|(b)||an extraordinary corporate transaction, such as a merger,reorganization or liquidation, involving the Issuer or any of its subsidiaries;|
|(c)||a sale or transfer of a material amount of assets of theIssuer or any of its subsidiaries;|
|(d)||any change in the present Issuer’s board of directorsor management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existingvacancies on the board;|
|(e)||any material change in the present capitalization or dividendpolicy of the Issuer;|
|(f)||any other material change in the Issuer’s businessor corporate structure;|
|(g)||one or more changes in the Issuer’s charter, bylawsor instruments corresponding thereto or other actions to the extent they may impede the acquisition of control of the Issuer byany person;|
|(h)||causing a class of securities of the Issuer to be delistedfrom a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registerednational securities association;|
|(i)||a class of equity securities of the Issuer becoming eligiblefor termination of registration pursuant to Section12(g)(4)of the Securities Exchange Act of 1934, as amended; or|
|(j)||any action similar to any of those enumerated above.|
|CUSIP No. 627335201||13D/A|
MusclePharm Corporation is a performance lifestyle company. The Company develops, manufactures, markets and distributes branded nutritional supplements. The Company offers a range of powders, capsules, tablets and gels. The Company’s portfolio of brands targets various types of fitness enthusiasts, including professional, combat sport, weight training, bodybuilding, running, basketball, soccer, cross fit, golf, tennis, volleyball and other active lifestyle activities. The MusclePharm Sport Series includes supplements that cover the needs of athletes, including their workout needs. MusclePharm Hybrid Series products include Assault, Amino1 and Combat Protein Powder. FitMiss products are designed and formulated for the active woman’s lifestyle utilizing ingredients that cover the range of busy women’s needs, including weight loss, multi-vitamins, protein shakes, detox, skin care and pre-workout energy mixes. MusclePharm Core products include BCAA 3:1:2, CLA Core and Fish Oil.
SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.
Insitutional Activity: The institutional sentiment increased to 2 in 2016 Q2. Its up 1.00, from 1 in 2016Q1. The ratio improved, as 0 funds sold all MusclePharm Corp shares owned while 0 reduced positions. 0 funds bought stakes while 0 increased positions. They now own 1.02 million shares or 0.00% without change from 1.02 million shares in 2016Q1.
Howard Capital Mngmt has 0.01% invested in the company for 10,000 shares. Wynnefield Capital Inc holds 0.98% or 1.01M shares in its portfolio.
The stock increased 6.63% or $0.12 on November 14, hitting $1.93. About 8,058 shares traded hands. MusclePharm Corp (OTCMKTS:MSLP) has declined 33.45% since April 13, 2016 and is downtrending. It has underperformed by 37.38% the S&P500.
MusclePharm Corporation is a performance lifestyle company. The company has a market cap of $25.71 million. The Firm develops, makes, markets and distributes branded nutritional supplements. It currently has negative earnings. The Firm offers a range of powders, capsules, tablets and gels.
More notable recent MusclePharm Corp (OTCMKTS:MSLP) news were published by: Businesswire.com which released: “MusclePharm Corp. Statement on SEC Settlement” on September 08, 2015, also Gurufocus.com with their article: “Is MusclePharm Corp going to have a bright future or will it fail?” published on July 06, 2015, Bloomberg.com published: “MusclePharm Paid Spa Tab for Ex-NFLer CEO and Spouse at Retreats” on May 06, 2015. More interesting news about MusclePharm Corp (OTCMKTS:MSLP) were released by: Benzinga.com and their article: “Colin Kaepernick’s Controversial Decision Won’t Affect Current Sponsors” published on August 30, 2016 as well as Seekingalpha.com‘s news article titled: “Medley Capital wins favorable MusclePharm settlement” with publication date: November 08, 2016.
According to Zacks Investment Research, “MusclePharm Corporation is a healthy lifestyle company. It develops and manufactures nutritional supplements which consist of amino acids, herbs, and proteins. The company’s product portfolio includes Assault, Battle Fuel, Bullet Proof, Combat Powder, MuscleGel, Shred Matrix, Re-con, Armor-V, BCAA 3:1:2, ZMA Max, Glutamine and Creatine. It sells its products through retail stores, distributors, and online stores as well as through a network of distributors internationally. MusclePharm Corporation is headquartered in Denver, Colorado.”
MSLP Company Profile
MusclePharm Corporation, incorporated on August 4, 2006, is a performance lifestyle company. The Firm develops, makes, markets and distributes branded nutritional supplements. The Firm offers a range of powders, capsules, tablets and gels. The Company’s portfolio of brands, including MusclePharm Sport Series and FitMiss, are marketed and sold in over 120 countries and available in approximately 50,000 retail outlets globally. The Firm focuses the MusclePharm Brand product portfolio for athlete’s and active lifestyle use. The Company’s portfolio of brands targets various types of fitness enthusiasts, including professional, combat sport, weight training, bodybuilding, running, basketball, soccer, cross fit, golf, tennis, volleyball and other active lifestyle activities. The Company’s principal international markets are Europe, the Middle East, Asia and South America.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.